<DOC>
	<DOC>NCT01890655</DOC>
	<brief_summary>To evaluate the long-term safety and tolerability of MT-1303 in subjects with relapsing remitting multiple sclerosis (RRMS).</brief_summary>
	<brief_title>Extension Study of MT-1303</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<criteria>Completion of the 24week treatment period in MT1303E04 as per protocol Able to provide written informed consent and to comply with the requirements of the protocol For males and females of reproductive potential, two methods of contraception must be used throughout the study and for 12 weeks after cessation of study medication. At least one of the methods of contraception must be a barrier method. Permanent discontinuation of study medication prior to the end of treatment (EOT) visit in MT1303E04 Newly diagnosed diabetes mellitus during MT1303E04</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>relapsing-remitting multiple sclerosis</keyword>
	<keyword>RRMS</keyword>
</DOC>